NERV
|Minerva Neurosciences Inc
NASDAQ
USD 1.77
-0.04|-2.21%
Current Price
USD 1.77
Change
USD -0.04 (-2.21%)
P/E Ratio
1.68
Dividend Yield
Market Cap
9.65M
Volume
2,204
Open
USD 1.81
Previous Close
USD 1.81
52-Week High
USD 3.69
52-Week Low
USD 1.15
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neur...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Remy Luthringer Ph.D.
Employees:8
Headquarters:Burlington, USA
Website:www.minervaneurosciences.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions